Biopharmaceutical company GSK plc (LSE:GSK) (NYSE:GSK) on Wednesday raised its guidance for the full year after reporting strong growth in the second quarter.
Turnover in the three months ended 30 June 2022 amounted to GBP6.9bn, up 19% or 13% at constant exchange rates.
Vaccine sales totalled GBP1.7bn, including a record quarter for the company's shingles vaccine Shingrix which generated GBP731m in sales.
Adjusted operating profit for the second quarter was GBP2.0bn, a year-on-year increase of 22% or 7% at constant exchange rates.
GSK now expects full-year sales to grow by 6% to 8% (previously 5% to 7%), with adjusted operating profit up 13% to 15% (previously 12% to 14%), excluding COVID-19 related revenues.
(USD1=GBP0.83)
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma